BIOXCEL THERAPEUTICS

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

01 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Termination of Proposed Public Offering

13 Feb 2024 09:00:43 By Nasdaq GlobeNewswire

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

12 Feb 2024 07:14:31 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Proposed Public Offering

08 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

11 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

30 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

14 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

08 Nov 2023 07:00:02 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

04 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

14 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023

31 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

29 Jun 2023 06:00:00 By Nasdaq GlobeNewswire